Innate Pharma S.A. (IPHYF)
USD 2.9
(0.0%)
USD 2.9
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 30.6 Million EUR | -23.77% |
| 2022 | 40.14 Million EUR | 197.33% |
| 2021 | 13.5 Million EUR | -20.31% |
| 2020 | 16.94 Million EUR | 2.12% |
| 2019 | 16.59 Million EUR | 422.61% |
| 2018 | 3.17 Million EUR | -29.77% |
| 2017 | 4.52 Million EUR | 11.27% |
| 2016 | 4.06 Million EUR | 29.73% |
| 2015 | 3.13 Million EUR | -16.55% |
| 2014 | 3.75 Million EUR | -10.77% |
| 2013 | 4.2 Million EUR | 26.42% |
| 2012 | 3.32 Million EUR | 0.0% |
| 2011 | - EUR | -100.0% |
| 2010 | 6.78 Million EUR | -10.17% |
| 2009 | 7.55 Million EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | -100.0% |
| 2006 | 2.72 Million EUR | 562.53% |
| 2005 | 411 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 26.41 Million EUR | 0.0% |
| 2024 Q1 | 26.41 Million EUR | -13.71% |
| 2023 Q1 | 35.32 Million EUR | -12.02% |
| 2023 Q2 | 35.32 Million EUR | 0.0% |
| 2023 Q4 | 30.6 Million EUR | -1.13% |
| 2023 Q3 | 30.95 Million EUR | -12.36% |
| 2023 FY | 30.6 Million EUR | -23.77% |
| 2022 Q2 | 12.52 Million EUR | 0.0% |
| 2022 Q1 | 12.52 Million EUR | -7.26% |
| 2022 FY | 40.14 Million EUR | 197.33% |
| 2022 Q3 | 40.14 Million EUR | 220.6% |
| 2022 Q4 | 40.14 Million EUR | 0.0% |
| 2021 Q3 | 13.5 Million EUR | -6.78% |
| 2021 FY | 13.5 Million EUR | -20.31% |
| 2021 Q4 | 13.5 Million EUR | 0.0% |
| 2021 Q2 | 14.48 Million EUR | 0.0% |
| 2021 Q1 | 14.48 Million EUR | -14.52% |
| 2020 Q2 | 16.78 Million EUR | 0.0% |
| 2020 Q4 | 16.94 Million EUR | 0.0% |
| 2020 FY | 16.94 Million EUR | 2.12% |
| 2020 Q1 | 16.78 Million EUR | 1.13% |
| 2020 Q3 | 16.94 Million EUR | 0.98% |
| 2019 Q4 | 16.59 Million EUR | 0.0% |
| 2019 FY | 16.59 Million EUR | 422.61% |
| 2019 Q1 | 3.23 Million EUR | 1.95% |
| 2019 Q2 | 3.23 Million EUR | 0.0% |
| 2019 Q3 | 16.59 Million EUR | 412.6% |
| 2018 FY | 3.17 Million EUR | -29.77% |
| 2018 Q4 | 3.17 Million EUR | 0.0% |
| 2018 Q3 | 3.17 Million EUR | -18.15% |
| 2018 Q2 | 3.87 Million EUR | 0.0% |
| 2018 Q1 | 3.87 Million EUR | -14.2% |
| 2017 FY | 4.52 Million EUR | 11.27% |
| 2017 Q4 | 4.52 Million EUR | 0.0% |
| 2017 Q3 | 4.52 Million EUR | 30.7% |
| 2017 Q2 | 3.45 Million EUR | 0.0% |
| 2017 Q1 | 3.45 Million EUR | -14.87% |
| 2016 Q3 | 4.06 Million EUR | 25.71% |
| 2016 FY | 4.06 Million EUR | 29.73% |
| 2016 Q4 | 4.06 Million EUR | 0.0% |
| 2016 Q2 | 3.23 Million EUR | 0.0% |
| 2016 Q1 | 3.23 Million EUR | 3.19% |
| 2015 Q1 | 3.52 Million EUR | -6.18% |
| 2015 Q2 | 3.52 Million EUR | 0.0% |
| 2015 Q3 | 3.13 Million EUR | -11.05% |
| 2015 Q4 | 3.13 Million EUR | 0.0% |
| 2015 FY | 3.13 Million EUR | -16.55% |
| 2014 Q2 | 3.98 Million EUR | 0.0% |
| 2014 Q3 | 3.75 Million EUR | -5.73% |
| 2014 Q4 | 3.75 Million EUR | 0.0% |
| 2014 FY | 3.75 Million EUR | -10.77% |
| 2014 Q1 | 3.98 Million EUR | -5.35% |
| 2013 Q2 | 2.92 Million EUR | 0.17% |
| 2013 FY | 4.2 Million EUR | 26.42% |
| 2013 Q4 | 4.2 Million EUR | 0.0% |
| 2013 Q3 | 4.2 Million EUR | 43.7% |
| 2013 Q1 | 2.92 Million EUR | -12.17% |
| 2012 Q4 | 3.32 Million EUR | 2439.69% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | 3.32 Million EUR | 0.0% |
| 2012 Q3 | 131 Thousand EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 FY | - EUR | -100.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | 6.78 Million EUR | -10.17% |
| 2010 Q4 | 6.78 Million EUR | 0.0% |
| 2009 FY | 7.55 Million EUR | 0.0% |
| 2009 Q4 | 7.55 Million EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | -100.0% |
| 2006 FY | 2.72 Million EUR | 562.53% |
| 2005 FY | 411 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -46.382% |
| Evofem Biosciences, Inc. | 8000.00 USD | -382487.5% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -1643.513% |
| Mesoblast Limited | 100.29 Million USD | 69.483% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -52092.967% |
| Genus plc | 228.2 Million USD | 86.588% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -4487.868% |
| ContraFect Corporation | 2.21 Million USD | -1284.932% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -2081.642% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -464.03% |
| MultiCell Technologies, Inc. | 36.43 USD | -84015820.944% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 44.963% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -1274.978% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -2391.694% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 81.574% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -1512.195% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -17774.788% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -555179.39% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | -11.71% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -9405.28% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.728% |
| Halberd Corporation | 150 Thousand USD | -20304.667% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -10102.333% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -18539.505% |
| argenx SE | 15.35 Million USD | -99.342% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -50.684% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -686771.634% |
| Genscript Biotech Corporation | 287.12 Million USD | 89.34% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -24133.187% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -13248.54% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -5418.852% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -120881.066% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -270.365% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -11422.202% |
| ONE Bio Corp. | 592.19 Thousand USD | -5068.373% |
| Reve Technologies, Inc. | 1064.00 USD | -2876497.744% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -20357.31% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -20357.31% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -13225.294% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -21607.092% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -38158.75% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -291.396% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -8193.479% |
| International Stem Cell Corporation | 445 Thousand USD | -6777.978% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -275.546% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -6597.374% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -2536.262% |
| PureTech Health plc | 18.25 Million USD | -67.71% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -20304.667% |
| IXICO plc | 275 Thousand USD | -11029.818% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -158.527% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -16.337% |
| CSL Limited | 11.23 Billion USD | 99.728% |
| Cellectis S.A. | 36.21 Million USD | 15.476% |